미국의 mRNA 합성 원료 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 부문별 예측(2025-2033년)

U.S. mRNA Synthesis Raw Materials Market Size, Share & Trends Analysis Report By Type (Capping Agents, Nucleotides, Plasmid DNA, Enzymes), By Application (Vaccine Production, Therapeutics Production), By End Use, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,356,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,760,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,569,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

미국의 mRNA 합성 원료 시장 요약

미국의 mRNA 합성 원료 시장 규모는 2024년에 5억 4,100만 달러로 평가되었습니다. 2033년에는 9억 3,220만 달러에 달하고, 2025-2033년 6.57%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 이러한 성장의 배경에는 mRNA 기술에 대한 학계 및 산업계의 관심 증가, mRNA 연구에 대한 자금 지원 증가, mRNA 기반 백신의 장점에 대한 인식 증가 등이 있습니다.

또한, RNA 기술의 치료적 응용이 증가함에 따라 예측 기간 동안 mRNA 합성 원료에 대한 수요가 크게 증가할 것으로 예측됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/보조 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 시장이 해결해야 할 과제 분석
• 업계 분석 툴
  • Porter의 Five Forces 분석
  • PESTEL 분석

제4장 유형 비즈니스 분석

• 유형 부문 대시보드
• 미국의 mRNA 합성 원료 시장 변수 분석
• 미국의 mRNA 합성 원료 시장 규모와 동향 분석(유형별, 2021-2033년)
• 캡핑제
  • CleanCap 시약
  • ARCA(Anti-Reverse Cap Analog)
  • 기타
• 뉴클레오티드
  • 수식 핵산
  • 천연 핵산
• 플라스미드 DNA
• 효소
  • 폴리메라아제
  • RNase 억제제
  • DNase
  • 기타
• 기타

제5장 용도 비즈니스 분석

• 용도 부문 대시보드
• 미국의 mRNA 합성 원료 시장 용도 변동 분석
• 미국의 mRNA 합성 원료 시장 규모와 동향 분석(용도별, 2021-2033년)
• 치료제 제조
• 백신 제조
• 기타 용도

제6장 최종 용도 비즈니스 분석

• 최종 용도 부문 대시보드
• 미국의 mRNA 합성 원료 시장 최종 용도 변동 분석
• 미국의 mRNA 합성 원료 시장 규모와 동향 분석(최종 용도별, 2021-2033년)
• 바이오의약품 및 제약회사
• CRO 및 CMO
• 학술연구기관

제7장 경쟁 구도

• 기업 분류
• 전략 매핑
• 기업 시장 현황 분석, 2024년
• 기업 개요/상장기업
  • F. Hoffmann-La Roche Ltd.
  • Jena Bioscience GmbH
  • Merck KGaA
  • Yeasen Biotechnology(Shanghai) Co., Ltd
  • BOC Sciences
  • Thermo Fisher Scientific, Inc.
  • Maravai LifeSciences
  • New England Biolabs
  • Creative Biogene
  • HONGENE
  • Evonik Industries AG
  • GENEVANT SCIENCES CORPORATION

LSH

영문 목차

영문목차

U.S. mRNA Synthesis Raw Materials Market Summary

The U.S. mRNA synthesis raw materials market size was estimated at USD 541.0 million in 2024 and is projected to reach USD 932.2 million by 2033, growing at a CAGR of 6.57% from 2025 to 2033. This growth is attributed to the growing academic & industrial interest in mRNA technology, increasing funding for mRNA research, and rising awareness of the advantages of mRNA-based vaccines.

Moreover, the increasing therapeutic applications of RNA technology are anticipated to provide significant demand for the mRNA synthesis raw materials over the forecast period.

U.S. mRNA Synthesis Raw Materials Market Report Segmentation

This report forecasts revenue growth in the U.S. and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. mRNA synthesis raw materials market report based on type, application, and end use:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Capping Agents
• CleanCap Reagents
• ARCA (Anti-Reverse Cap Analog)
• Others
• Nucleotides
• Modified Nucleic Acids
  • N1-methylpseudouridine-triphosphate
  • 5-Methylcytidine triphosphate (5mCTP)
  • Others
• Natural Nucleic Acids
  • Adenine
  • Guanine
  • Cytosine
  • Uracil
• Plasmid DNA
• Enzymes
• Polymerase
• RNase Inhibitor
• DNase
• Others
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Vaccine Production
• Therapeutics Production
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical & Pharmaceutical Companies
• CROs & CMOs
• Academic & Research Institutes

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Type Segment
  • 1.1.2. Application Segment
  • 1.1.3. End Use Segment
• 1.2. Estimates and Forecast Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Primary Research
• 1.5. Information or Data Analysis:
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objective

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing academic & industrial interest in mRNA technology
    • 3.2.1.2. Advantages of mRNA vaccines
    • 3.2.1.3. Increasing funding for mRNA research
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Nonexistence of effective government regulations for mRNA-based product approvals
    • 3.2.2.2. High cost of mRNA synthesis raw materials
  • 3.2.3. Market Challenge Analysis
    • 3.2.3.1. Lack of long-lasting and affordable manufacturing processes
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. Type Business Analysis

• 4.1. Type Segment Dashboard
• 4.2. U.S. mRNA Synthesis Raw Materials Market Type Movement Analysis
• 4.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.4. Capping Agents
  • 4.4.1. Capping agents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. CleanCap Reagents
    • 4.4.2.1. CleanCap reagents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. ARCA (Anti-Reverse Cap Analog)
    • 4.4.3.1. ARCA (anti-reverse cap analog) market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Nucleotides
  • 4.5.1. Nucleotides market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Modified Nucleic Acids
    • 4.5.2.1. Modified nucleic acids market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.2.2. N1-methylpseudouridine-triphosphate
      • 4.5.2.2.1. N1-methylpseudouridine-triphosphate market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.2.3. 5-Methylcytidine triphosphate (5mCTP)
      • 4.5.2.3.1. 5-Methylcytidine triphosphate (5mCTP) market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.2.4. Others
      • 4.5.2.4.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Natural Nucleic Acids
    • 4.5.3.1. Natural nucleic acids market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.3.2. Adenine
      • 4.5.3.2.1. Adenine market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.3.3. Guanine
      • 4.5.3.3.1. Guanine market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.3.4. Cytosine
      • 4.5.3.4.1. Cytosine market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.3.5. Uracil
      • 4.5.3.5.1. Uracil market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Plasmid DNA
  • 4.6.1. Plasmid DNA market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.7. Enzymes
  • 4.7.1. Enzymes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7.2. Polymerase
    • 4.7.2.1. Polymerase market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7.3. RNase Inhibitor
    • 4.7.3.1. RNase inhibitor market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7.4. DNase
    • 4.7.4.1. DNase market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7.5. Others
    • 4.7.5.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Application Business Analysis

• 5.1. Application Segment Dashboard
• 5.2. U.S. mRNA Synthesis Raw Materials Market Application Movement Analysis
• 5.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Therapeutics Production
  • 5.4.1. Therapeutics production market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Vaccine Production
  • 5.5.1. Vaccine production market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. Other Application
  • 5.6.1. Other application market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. End Use Business Analysis

• 6.1. End Use Segment Dashboard
• 6.2. U.S. mRNA Synthesis Raw Materials Market End Use Movement Analysis
• 6.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Biopharmaceutical & Pharmaceutical Companies
  • 6.4.1. Biopharmaceutical & pharmaceutical companies market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. CROs & CMOs
  • 6.5.1. CROs & CMOs market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Academic & Research Institutes
  • 6.6.1. Academic & research institutes market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Strategy Mapping
• 7.3. Company Market Position Analysis, 2024
• 7.4. Company Profiles/Listing
  • 7.4.1. F. Hoffmann-La Roche Ltd.
    • 7.4.1.1. Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. Jena Bioscience GmbH
    • 7.4.2.1. Overview
    • 7.4.2.2. Product Benchmarking
    • 7.4.2.3. Strategic Initiatives
  • 7.4.3. Merck KGaA
    • 7.4.3.1. Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Yeasen Biotechnology (Shanghai) Co., Ltd
    • 7.4.4.1. Overview
    • 7.4.4.2. Product Benchmarking
    • 7.4.4.3. Strategic Initiatives
  • 7.4.5. BOC Sciences
    • 7.4.5.1. Overview
    • 7.4.5.2. Product Benchmarking
    • 7.4.5.3. Strategic Initiatives
  • 7.4.6. Thermo Fisher Scientific, Inc.
    • 7.4.6.1. Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. Maravai LifeSciences
    • 7.4.7.1. Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. New England Biolabs
    • 7.4.8.1. Overview
    • 7.4.8.2. Product Benchmarking
    • 7.4.8.3. Strategic Initiatives
  • 7.4.9. Creative Biogene
    • 7.4.9.1. Overview
    • 7.4.9.2. Product Benchmarking
    • 7.4.9.3. Strategic Initiatives
  • 7.4.10. HONGENE
    • 7.4.10.1. Overview
    • 7.4.10.2. Product Benchmarking
    • 7.4.10.3. Strategic Initiatives
  • 7.4.11. Evonik Industries AG
    • 7.4.11.1. Overview
    • 7.4.11.2. Financial Performance
    • 7.4.11.3. Product Benchmarking
    • 7.4.11.4. Strategic Initiatives
  • 7.4.12. GENEVANT SCIENCES CORPORATION
    • 7.4.12.1. Overview
    • 7.4.12.2. Product Benchmarking
    • 7.4.12.3. Strategic Initiatives

관련자료